Unique ID issued by UMIN | UMIN000019172 |
---|---|
Receipt number | R000022099 |
Scientific Title | Balloon assisted chemoembolization (BACE) for hepatocellular carcinoma: evaluation of safety and efficary |
Date of disclosure of the study information | 2015/10/01 |
Last modified on | 2015/10/01 08:58:11 |
Balloon assisted chemoembolization (BACE) for hepatocellular carcinoma: evaluation of safety and efficary
Balloon assisted chemoembolization (BACE)
Balloon assisted chemoembolization (BACE) for hepatocellular carcinoma: evaluation of safety and efficary
Balloon assisted chemoembolization (BACE)
Japan |
hepatocellular carcinoma
Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery | Radiology |
Malignancy
NO
To evaluate the safety and efficacy of balloon assisted chemoembolization (BACE) for hepatocellular carcinoma
Safety,Efficacy
To evaluate the safety of BACE, adverse events except for the side effects of chemoembolization are assessed according to SIR(Society of interventional radiology) standards of practice committee classification of complications by outcome.
The efficacy of BACE is assessed on contrast enhanced CT or MRI after 3 month according to RECICL classification.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment |
In cases where a large volume of normal hepatic parenchyma is expected to be damaged by ordinary chemoembolization, a microballoon catheter is used to temporarily occlude the artery perfusing the normal hepatic parencyma and chemoembolization is performed through another microcatheter.
20 | years-old | <= |
Not applicable |
Male and Female
1)Diagnosis of hepatocellular carcinoma according to EASL guideline
2)Chemoembolization is indicated.
3)Performance status of 0-2
4)Liver function of Child-pugh A or B
5)eGFR is 30mL/min/1.73m2 or more
6)Platelet count of 50,000 microL or more
7)No previous treatment or 4 weeks after the previous treatment
8)Informed consent is obtained.
1)Rupture of hepatocellular carcinoma
2)History of surgical or endoscopic treatment of bile duct
3)Prominent arterioportal or arteriovenous shunts
4)Dissection or stenosis of 50% or more in the celiac trunk or hepatic artery
5)Hepatic coma or severe psychiatric disorder
6)Severe drug allergy including iodine contast allergy
7)Inadequate patients to undergo the procedure safely
52
1st name | |
Middle name | |
Last name | Kensaku Mori |
Faculty of Medicine, University of Tsukuba
Department of Radiology
1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575 Japan
0298533205
moriken@md.tsukuba.ac.jp
1st name | |
Middle name | |
Last name | Kensaku Mori |
Faculty of Medicine, University of Tsukuba
Department of Radiology
Faculty of Medicine, University of Tsukuba
0298533205
moriken@md.tsukuba.ac.jp
University of Tsukuba Hospital
faculty research funds
Ibaraki prefectural central hospital
NO
University of Tsukuba Hospital and Ibaraki Prefectural Central Hospital(Ibaraki)
2015 | Year | 10 | Month | 01 | Day |
Unpublished
Open public recruiting
2015 | Year | 10 | Month | 01 | Day |
2015 | Year | 10 | Month | 01 | Day |
2016 | Year | 12 | Month | 31 | Day |
2016 | Year | 12 | Month | 31 | Day |
2016 | Year | 12 | Month | 31 | Day |
2017 | Year | 03 | Month | 31 | Day |
2015 | Year | 09 | Month | 30 | Day |
2015 | Year | 10 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022099
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |